Nektar Therapeutics
NKTRNASDAQHealthcare● Active
$56.19
$-1.13(-1.97%)
Market Cap$1.1B
P/E Ratio—
52W High$109
52W Low$7.99
Nektar Therapeutics (NKTR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NKTR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M |
| Cost of Revenue | $0.00M | $30.69M | $36.64M | $21.64M | $24.90M |
| Gross Profit | $55.23M | $67.74M | $53.48M | $70.42M | $77.01M |
| Gross Margin %(computed) | 100.00% | 68.82% | 59.34% | 76.50% | 75.57% |
| Operating Expenses | |||||
| R&D Expenses | $117.33M | $120.91M | $114.16M | $218.32M | $400.27M |
| G&A Expenses | $68.67M | $76.75M | $77.42M | $92.33M | $122.84M |
| Total Operating Expenses | $186.00M | $172.94M | $190.90M | $310.66M | $523.11M |
| Operating Income | ($130.77M) | ($105.20M) | ($137.43M) | ($240.24M) | ($446.10M) |
| Operating Margin %(computed) | -236.77% | -106.88% | -152.49% | -260.97% | -437.76% |
| Interest Income | $10.44M | $14.50M | $19.01M | $6.78M | $2.73M |
| Interest Expense | $26.18M | $28.11M | $25.33M | $28.91M | $47.31M |
| Income Before Tax | ($164.21M) | ($119.20M) | ($276.26M) | ($364.98M) | ($523.28M) |
| Income Tax Expense | ($0.14M) | ($0.24M) | ($0.20M) | $3.21M | $0.56M |
| Net Income | ($164.08M) | ($118.96M) | ($276.06M) | ($368.20M) | ($523.84M) |
| Net Margin %(computed) | -297.07% | -120.86% | -306.31% | -399.98% | -514.03% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-9.73 | $-8.68 | $-21.79 | $-29.51 | $-42.90 |
| Wtd Avg Shares | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M |
| EBITDA | ($129.74M) | ($86.70M) | ($243.11M) | ($323.87M) | ($461.82M) |
| EBITDA Margin %(computed) | -234.91% | -88.08% | -269.75% | -351.82% | -453.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Nektar Therapeutics data
About Nektar Therapeutics (NKTR) Income Statement
Nektar Therapeutics (NKTR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NKTR reported revenue of $0.06B, gross profit of $0.06B (gross margin 100.00%), and net income of ($0.16B) — a net profit margin of -297.07%.
Frequently asked questions
NKTR · 4 questionsNektar Therapeutics (NKTR) reported revenue of $0.06B for 2025, down 43.9% year-over-year.
NKTR revenueNKTR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08